Amgen submitted new analyses to FDA supporting Tavneos staying on market, disputing data manipulation claims.
July 24, 2026 02:07 PM EDT
Amgen shares new analysis with FDA in bid to keep Tavneos on the market
Amgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market.
The
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth…
Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the…
EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the…
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
